Articles tagged with Tumor Development
Researchers have found that alterations in the blood immune system increase cancer risk, and identified over 1,000 genes influencing this regulation. The study also discovered protective roles of certain immune cells against common cancers.
Scientists have discovered a way to predict breast cancer risk based on specific chemical traits, identifying over 900 chemicals that could contribute to the disease. These chemicals are commonly found in consumer products, food, and workplaces, and can alter hormones or damage DNA.
Researchers have developed a novel tool for the selective and efficient recovery of large DNA molecules using TAR cloning. This technique has been applied to isolate individual gene alleles, study genome architecture and evolution, and engineer synthetic viruses with novel properties, including vaccine development.
Researchers Haval Shirwan and Esma Yolcu design a molecule, SA-4-1BBL, that mobilizes immune cells to target cancer cells. The molecule shows promising results in preventing lung cancer by triggering the immune system's defense mechanism.
Researchers found that cancer cells with multiple mutations alter cell competition, allowing them to infiltrate and form highly invasive tumors. The study identified a key mechanism, MMP21, which promotes the production of diffusely invasive cancer cells.
Research reveals chromatin's role in preventing DNA-RNA hybrid formation, which causes genomic instability and cancer. DNA-RNA hybrids are a risk factor in tumour development, suggesting potential use as an indicator of carcinogenic risk.
Researchers identified a promising dual-purpose target, KDM1A, using AI analysis of transcriptomic data from 16,740 healthy samples and 11,303 tumors. KDM1A was found to significantly extend lifespan in Caenorhabditis elegans and has anti-cancer activities established in preclinical and clinical studies.
A novel droplet digital PCR assay detects KMT2A fusion markers in AML patients, enabling sensitive MRD detection and guiding treatment decisions. This breakthrough may improve patient outcomes by assessing response to therapy and long-term surveillance.
The study found that SPT5 plays an important role in the development of MYC-dependent tumors, with reduced levels leading to significant regression of tumors. The researchers suggest that SPT5 could be a potential target for pharmacological inhibitors to combat cancer.
Researchers at Xi'an Jiaotong-Liverpool University have developed a sensitive and robust pH sensor that can detect pH variation in just a few microliters of samples. The new sensor uses novel materials and methods to overcome the current method's limitations, which are not sensitive enough or fragile for commercial-scale use.
Researchers developed an environmental risk score to assess ALS risk and survival using a blood sample, associating several individual pollutants with disease risk. A mixture of pesticides in the blood significantly increased ALS risk, with those in the highest group having twice the risk as those in the lowest.
A study of 9,479 participants identified racial and ethnic disparities in breast cancer survival, highlighting the need for targeted interventions to improve outcomes for at-risk subgroups. The findings suggest that focused care approaches can address these disparities and promote more equitable treatment.
A large-scale prospective study identified significant variations in the gut microbiome of individuals who developed pre-cancerous colonic lesions. These findings suggest that the microbiome could act as a valuable tool to improve existing tests, advancing early detection methods for colorectal cancer.
TTUHSC researchers received funding for pilot studies on photothermal tumor therapy, clear cell renal cell carcinoma, and colorectal cancer screening in underserved areas. The grants support the purchase of a cell sorter and address regional health disparities.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
Researchers found that patients with HPV-positive cancers develop recurrent disease significantly later than those that were HPV-negative, and also are more likely to spread to the lungs. A new, highly sensitive blood test has been developed to detect cancer earlier, using a framework for combining routine blood testing and imaging.
Chung-Ang University researchers create an electrochemical DNA biosensor that detects HPV-16 and HPV-18 with high specificity, facilitating early diagnosis of cervical cancer. The sensor uses a graphitic nano-onion/MoS2 nanosheet composite to enhance conductivity.
Researchers discovered that inhibiting IGF2BP1 can extinguish its cancer-causing effects, leading to the formation of neuroblastomas. The study provides a promising new potential therapeutic approach for treating this childhood cancer.
A team of KAUST researchers has found a critical protein that regulates cell division and proliferation in breast cancer and leukemia. Their work clears the way for the development of targeted drugs by refuting recent challenges to their approach.
Researchers found all hallmarks of T cell exhaustion within six to 12 hours of tumor exposure, including dramatic changes in gene expression and chromatin accessibility. The study challenges existing ideas about how T cells become exhausted and has implications for cancer immunotherapies.
Researchers have found a key role for NFIC in acinar cell maturation and limiting tumour formation in the pancreas. The molecule helps acinar cells work properly, reducing the risk of pancreatic cancer.
A novel association of t(5;17) with t(8;21) has been reported in an acute myeloid leukemia (AML) patient, resulting in a RUNX1-RUNX1T1 rearrangement. The patient received chemotherapy and stem cell transplantation, highlighting the importance of this rare translocation.
Researchers identified a new mechanism by which cancer hijacks enzyme substrate motif mutations, enabling tumor growth and therapy resistance. The study found that colorectal cancer hijacks BUD13 mutations to inactivate a key tumor suppressor, Fbw7.
A study published in Cancer Research identifies a novel mechanism by which liver cancer develops, involving the aberrant activation of the Wnt signaling pathway and the gene GREB1. The research reveals that GREB1 is responsible for integrating conflicting cellular states of differentiation and proliferation, leading to tumor promotion.
A recent study has found that impaired histone inheritance accelerates breast cancer growth and metastasis by disrupting the epigenetic state of cells. This disruption leads to the reactivation of genes associated with development, promoting tumor progression.
A study by Martin-Luther-University Halle-Wittenberg found a link between high levels of IGF2BP2 and faster-growing bowel cancer tumours with chemotherapy resistance. The protein's role in cell growth and metabolism may lead to the development of new diagnostic procedures and therapeutic strategies.
Researchers found that MALAT1 inhibition decreased BRAF RNA and protein levels, while increasing correlation with MAPK-associated genes. MALAT1-ASO treatment also reduced melanoma cell growth and tumor size in xenograft models.
Scientists have developed a gene-editing technique that allows them to easily engineer specific cancer-linked mutations into mouse models. This new method, based on CRISPR genome-editing technology, enables researchers to explore many unknown mutations and develop new drugs targeting those mutations.
A new study has provided insight into the mysterious evolution of DNA rings in tumors, revealing that nearly one-third of all tumors have these genetic structures. The researchers used a technology to trace the path of DNA ring development in neuroblastoma cells, finding that large rings contain cancer genes spurring cell growth.
Researchers at The Wistar Institute have uncovered a key mechanism by which the p53 gene suppresses tumors. They discovered that a specific genetic variant, found in African Americans, triggers immune function that kills tumors.
Researchers discuss the importance of biomarkers in breast lump management, enabling patients to make informed decisions between proactive treatment and watchful waiting. The development of biomarkers could provide personalized risk assessments and guide treatment strategies for women with breast lumps.
Children's Hospital Los Angeles researchers have identified a disruption in early kidney progenitor cell development linked to the formation of Wilms tumor. The study found that these cells can reproduce the original tumor and are aggressive, drug-resistant, and metastasize like cancer cells.
Researchers investigated the roles of STAT3α and STAT3β in aggressive breast cancer and found that differential silencing of these isoforms leads to changes in STAT3 activation. This study emphasizes the importance of distinguishing between STAT3 isoforms for accurate cancer diagnosis and therapy.
Researchers identify SRSF1 as a key player in promoting pancreatitis and pancreatic cancer growth. High levels of SRSF1 are associated with worse patient outcomes, highlighting its potential as a target for new therapies.
A new MYC inhibitor, Omomyc, has shown promising preclinical results in reducing melanoma tumor growth and metastatic capacity by halting the transcription of genes implicated in cell growth and proliferation. The study demonstrates a good prognostic gene signature in melanoma patients with this approach.
A multicenter study found stereotactic radiosurgery to be highly effective in controlling vestibular schwannoma growth in NF2 patients while maintaining serviceable hearing. The procedure was also shown not to cause radiation-related tumor development or malignant transformation, addressing long-standing concerns.
A study led by Tokyo University of Science researchers identified Dectin-1's role in promoting colorectal cancer by enhancing PGE2 production and suppressing IL-22BP expression. The study used mouse models and clinical samples to validate the findings, which have immediate clinical implications for CRC patients.
The University of Texas at El Paso will study the role of obesity and inflammation in pancreatic cancer development, a disease with high mortality rates. The grant aims to develop targeted treatments and preventives, potentially transforming understanding of pancreatic cancer.
A new PET/CT scanner prototype has shown promising results in preclinical testing, offering higher resolution and accurate tumor assessment. The scanner aims to enhance treatment planning for head and neck cancers, which have a low five-year survival rate and high recurrence rate.
The new medicine has shown promising results in a Phase 1 clinical trial, with 70% of patients stable after six weeks and one patient remaining stable for over two years. Developed by NTNU researcher Marit Otterlei, ATX-101 targets cancer cells' stress regulation system, leaving healthy cells unaffected.
Researchers created a three-dimensional structure that mimics bone and houses osteosarcoma cells beside immune cells, finding increased inflammation reduces chemotherapy effectiveness. The study highlights the importance of the tumor microenvironment in disease progression and treatment.
Cancer develops when genome doubling leads to chromatin disorganization, promoting oncogene activation and genomic instability. Researchers found that WGD causes sub-compartment repositioning and loss of chromatin segregation.
A recent study analyzed 7,301 metastatic breast cancer patients with MTAP loss, revealing younger age, higher TNBC cases, and BRCA1 mutations. The findings also suggest potential therapeutic agents targeting PRMT5 and MTA2 in MTAP-deficient cancers.
Researchers from China conducted a comprehensive review of dual therapy (DT) for H. pylori eradication, highlighting its high efficacy and patient compliance with minimal adverse events. High-dose DT administered over 14 days has emerged as the most effective treatment option.
Children with Down syndrome are highly vulnerable to developing aggressive leukaemia due to a defect in the RUNX1 gene, which regulates blood cell formation. Researchers have identified a specific variant of the gene that promotes leukaemia development and discovered potential therapeutic approaches to correct this malfunction.
Researchers have identified mitochondrial signaling pathways as critical organelles that promote tumorigenesis and metastasis. In particular, the integrated stress response is found to engage with mitochondria to drive tumor growth, highlighting a new paradigm for understanding aggressive prostate cancer progression.
Researchers from Northwestern University discuss the multifaceted tumorigenic functions of EZH2, including its role in regulating translation and coactivating transcription. This new understanding may provide novel insights into advancing EZH2-targeting strategies for prostate cancer patients.
A new study found that military veterans are at higher risk of developing human papillomavirus (HPV)-related cancers due to low vaccination rates. The study suggests that 'catch-up' HPV vaccination campaigns are needed to boost vaccination rates among veterans and reduce deaths from these largely preventable cancers.
A study found that BRCA1 mutations increase the risk of malignant mesothelioma caused by asbestos exposure. People with this genetic defect are more susceptible to tumor growth due to impaired ferroptosis defense mechanisms.
Researchers found that MMTV-NeuT/ATTAC mice treated with anti-PD-1 therapy developed increased tumor-associated macrophages, EMT, fibroblast proliferation, and enhanced extracellular matrix. These findings suggest potential therapeutic avenues to enhance PD-1 immune checkpoint sensitivity.
Researchers identified two broad categories of MPNSTs based on their molecular makeup, one of which has a higher number of immune cells and tends to be more survivable. This discovery may lead to new treatment approaches for NF1 patients with MPNSTs, including immunotherapy and genetic testing.
Researchers have discovered that calcitriol, a form of activated vitamin D3, inhibits arsenic-mediated carcinogenesis in human skin cells. The treatment significantly reduced arsenic levels and suppressed anchorage-independent growth in both keratinocytes and lung epithelial cells.
Researchers discovered PDGF cross-signaling through alternative receptors in colorectal cancer cells, enabling bypassed signaling. This finding supports anti-PDGF therapy as a combination strategy alongside VEGF and EGF targeting.
Researchers found that simultaneously targeting two signalling switches can severely inhibit tumour angiogenesis, cancer growth and metastasis in multiple models of cancer. This approach has the potential to restrict a cancer's ability to escape therapy by rapidly destroying the VEGF receptor when both receptors are targeted.
Researchers visualized the (pro)renin receptor's protein binding site and found hand-shaped grooves allowing for multiple protein binding. The study provides new insight into disease pathogenesis and aids in exploring novel treatments.
A new review paper discusses the role of CDK4 in regulating the cell cycle and its involvement in cancer. The study highlights the importance of CDK4/6 inhibitors as treatments for ER+ breast cancer and their potential utility in multiple tumor types.
Scientists at Northwestern Medicine have discovered a causal link between environmental phthalates and increased uterine fibroid growth. Exposure to certain phthalates, such as DEHP, may activate a hormonal pathway that causes fibroid tumors to grow. This study explains the mechanisms behind this association.
A study reveals that interleukin 34 (IL-34) modulates the balance between two myeloid-derived suppressor cell populations, leading to immunosuppression and chemoresistance in triple-negative breast cancer. Neutralizing IL-34 with a drug reduces tumor growth and susceptibility to chemotherapy.
Researchers have developed a drug compound that stops cancer cell growth in mice with little effect on normal healthy cells, making it potentially nontoxic for patients. The therapy targets the epidermal growth factor receptor gene, which is overexpressed in about half of all triple-negative breast cancer cases.